Org 9426, the 2-morpholino,3-hydroxy,16N-alkyl pyrrolidino analogue of vecuronium, is a new aminosteroid neuromuscular blocking drug currently undergoing clinical trial. Org 9426, in common with vecuronium, possesses a medium-duration time course of action (between those of suxamethonium and pancuronium) in experimental animals [1-3] and in humans [4] . It differs from vecuronium in having a more rapid onset of action from the time of injection to a 75 % block of muscle twitch [1, 4] . In a previous electrophysiological study [1], we showed that Org 9426 reduced the amplitude of end-plate currents (EPC) without producing voltage-dependent changes in the time course of current decay. These results were interpreted as indicating that Org 9426 had little end-plate ion channel blocking activity and that its major effect, in common with that of the other neuromuscular blocking drugs in clinical use, was probably caused by block of postjunctional acetylcholine receptors. However, there is evidence that myoneuronal blockers in clinical use possess a measure of prejunctional activity in addition to their well-established postjunctional receptor blocking action. Thus train-offour and tetanic fade produced by non-depolarizing neuromuscular blocking drugs in intact muscles have been suggested to be caused by prejunctional actions of the drugs to inhibit a nicotinic receptormediated positive feedback of transmitter release during high frequency stimulation [5] [6] [7] . This suggestion is based on the differential ability of a range of nicotinic receptor antagonists to produce tetanic fade in relation to their ability to produce block of singly evoked twiches [8, 9] , and on the ability of such antagonists to produce rundown of the amplitudes of successive neurally evoked EPC in a train of impulses without producing rundown of EPC induced by iontophoretic application of acetylcholine [10, 11] .
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Clearly, any activity of a neuromuscular blocking drug on rapidly stimulated muscles is relevant to its clinical use, as voluntary movement is initiated by trains of nerve impulses rather than by single impulses. Thus, in order to assess the action of Org 9426 on rapidly stimulated muscles and to test its potential prejunctional activity at the putative nicotinic autoreceptor, we have studied the ability of the drug to produce tetanic fade and EPC amplitude rundown in the isolated rat hemidiaphragm nervemuscle preparation.
MATERIALS AND METHODS

Tension recording
Single twitches and tetani were recorded from hemidiaphragms isolated from male SpragueDawley rats (200-300 g), mounted at 32 °C in Krebs-Henseleit solution of the following composition (mmol litre" 1 ): NaCl 118; KC1 5; CaCl, 2.5; NaHCO 3 25; KH 2 PO 4 1.2; MgSO 4 1; glucose 11; gassed with 5 % carbon dioxide in oxygen (pH 7.2-7.4). The phrenic nerve was stimulated with rectangular pulses of 0.2 ms duration and a voltage greater than twice that required to produce a maximal twitch. Single twitches were elicited continuously at 0.1 Hz and a tetanus at 50 Hz for 2.0 s was elicited every 10 min. Tetanic fade was calculated as the loss of tension at the end of the tetani expressed as a percentage of the peak tetanic tension. Tension responses were reorded on a chart recorder via Grass FT03C or FT IOC semi-isometric force displacement transducers. Data are presented as means (SEM) of results from six muscle preparations.
Electrophysiological recordings
The cut rat hemidiaphragm muscle preparation used has been described extensively elsewhere [10, 12, 13] . Briefly, hemidiaphragm preparations with 10-20 mm of the phrenic nerve supply were removed from male Sprague-Dawley rats (150-250 g) killed by a blow to the head followed by rapid exsanguination. The nerve-muscle preparation was pinned to the Sylgard (Dow Corning) base of a 5-ml tissue bath which was perfused continually (10-lSmlmin" 1 ) with standard Krebs-Henseleit physiological solution at room temperature (18-22 °C) . EPC were recorded from muscle fibre end-plates using a conventional two-microelectrode voltage clamp system modified from that of Dionne and Stevens [14] . Microelectrodes were filled with either potassium chloride 3 mol litre" 1 (voltage recording) or potassium sulphate 0.6 mol litre" 1 (current passing) and had resistances of 2-5 Mfl. The phrenic nerve was stimulated via silver wire electrodes with trains of 50 pulses at 50 Hz and of 50-100 (is pulse duration and voltage greater than that required to produce EPC. Muscle contraction in response to nerve stimulation was prevented by cutting the muscle fibres at each end, approximately 3 mm from the central nerve band, as described previously [10] . In each preparation, EPC trains were recorded from a single fibre at holding potentials of -30 to -80 mV in 10-mV steps before and 5-10 min after the application of Org 9426 2-8 x 10"* mol litre" 1 . EPC trains were separated by a minimum period of rest of 30 s, an interval which ensured full recovery of the amplitude of the first EPC. Clamp gain was adjusted so that the membrane potential changed by less than 1 % of the driving force (holding potential -reversal potential) during EPC.
All EPC trains were recorded on FM tape (Racal Store 4DS, DC-5 kHz) for subsequent computer analysis. After low-pass filtering at 3-5 kHz, signals from tape with a minimum of 2.5 ms of pre-rising phase baseline, were digitized at 25 kHz using an analogue-to-digital converter (Data Translation, DT 2801A) and analysed by a laboratory computer (Vanilla, SX-386) using a suite of purpose-designed analysis programs [15] . All EPC were inspected individually and artefacts caused by electrical interference or vibrations were eliminated. Each individual EPC was analysed for peak amplitude and time constant of decay (r EPC ). For each train of EPC, EPC rundown was calculated as the average loss of amplitude of the last 10 EPC in the train as a percentage of the amplitude of the first EPC. The number of packets of transmitter released per nerve impulse towards the end of the trains (the EPC quantal content, m) was estimated from the last 35-40 EPC using the method of variance [16] :
The mobilization rate, estimated from the number of quanta released per second towards the end of the train of stimuli, was calculated as the product of the stimulation frequency and the mean EPC quantal content at the end of the train of EPC [17] . Values for the voltage-dependence of T EPC and for the membrane reversal potential, that is the membrane potential at which the EPC amplitude was effectively 0 mV, were calculated from straight line regression fits to In(T EPC ) or EPC amplitude values, respectively, recorded at six different membrane potentials. Finally, for each EPC variable, mean and SEM values were calculated from data from seven different preparations. All data recorded in the absence and presence of Org 9426 were compared using paired Student's t tests (two-tailed). In all statistical tests, significance was set as P < 0.05.
Drugs
The drugs used were the bromide salt of Org 9426 (2-morpholino, 16-allyl-pyrrolidino derivative of the 3-desacetoxy analogue of vecuronium) and neostigmine methylsulphate.
RESULTS
Effects of Org 9426 and vecuronium on tetanic fade
A concentration of Org 9426 5 x 10"" mol litre" 
Effects of Org 9426 on end-plate current rundown
In order to differentiate any potential prejunctional activity from postjunctional ion channel blocking activity, the effects of Org 9426 2-8 x 10~8 mol litre" 1 on the rundown of EPC during high frequency trains of nerve impulses, and on the amplitude and time constant of the first EPC in the train, were examined at several membrane potentials. In control trains of EPC, recorded in the absence of any blocking drug, the amplitude of successive EPC in the train diminished until, after approximately 10 impulses, a plateau was reached. The quantal content at this plateau, estimated by the method of variance, was 170 (32) (« = 7, -70mV). The mobilization rate was 8500 (1600) quanta s" 1 (n = 7, -70 mV). All three concentrations of Org 9426 used reduced the overall amplitude of the EPC in the train compared with those in control trains. In addition, Org 9426 produced a significantly greater rundown of the amplitude of successive EPC than that seen in control trains recorded in the absence of the drug ( fig. 1 ). With the greatest concentration of Org 9426 used (8 x 10~8 mol litre" 1 ) (selected for further analysis to facilitate comparison with results for vecuronium obtained previously [11] ), the amplitude of the first EPC in the train was reduced by 68.2 (6.9) % (n = 7, -70 mV) compared with controls in the absence of drug. This reduction was not voltage-dependent, a similar percentage reduction in EPC amplitude being seen at all holding potentials studied ( fig. 2A) and, from extrapolation, no change was detected in the membrane reversal potential: control, -8.8 (2.6) mV (« = 7); Org 9426 8 x 10"* mol litre" 1 , -6.0 (3.5) mV (n = 7). The time constant of decay of the first EPC in the train (r EPC ) was reduced by 33.1 (3.1)% (« = 7, -70 mV) compared with controls. Normally, the decay time constant of EPC (an approximate estimate of channel open time) is highly dependent on: membrane potential-that is, it is voltage-dependent, T EPC being related exponentially to the membrane potential. Thus, in control trains, the membrane potential change required for an e-fold decrease in r EPC (the H value) was 118.9 (7.2) mV (n = 7). Drugs which block end-plate ion channels reduce this voltage-dependence [18] and this is seen as an increase in the H value. However, Org 9426 8 x 10" 6 mol litre" 1 produced no statistically significant change in the voltage-dependence of T EPC ( fig.  2 B) , the H value in the presence of the compound being 121 (15)mV(n = 7).
BRITISH JOURNAL OF ANAESTHESIA
The EPC amplitude rundown measured in the presence of Org 9426 8 x 10" 6 mol litre" 1 , in common with that in controls, was not dependent upon membrane potential (fig. 3) . Rather, the enhanced EPC amplitude rundown was associated with an increase in the variance of EPC amplitudes during the plateau part of the train. Quanta! content assessed from this variance was 59 (14) (n = 7, -70 mV), and the mobilization rate was 2950 (700) quanta s" 1 (n = 7, -70 mV). Both these values are significantly less (approximately 67 % reduction) than those in control trains in the absence of Org 9426 (P < 0.05).
DISCUSSION
Our data indicate that, in common with most other non-depolarizing nicotinic antagonists (the exception being the irreversible a snake toxins [9] ), Org 9426 possesses a prejunctional action, probably on nicotinic autoreceptors. Thus the compound produced tetanic fade at smaller concentrations than those necessary to produce an equivalent degree of block of single twitches, and it produced rundown of the amplitudes of successive EPC that was greater than that seen in control trains. It is conceivable that end-plate ion channel block could explain EPC train rundown [10] and Org 9426, as shown previously [1] , did reduce T EPC , a potential indicator of mean channel open time. However, the effects of Org 9426, like those of tubocurarine [10] and vecuronium [11] , but unlike the effects of the channel blocker trimetaphan [10] , were not dependent upon membrane potential. Such a non-voltage-dependent reduction in r EPC can be explained in terms of a postjunctional receptor block reducing the repetitive binding of the transmitter acetylcholine to the receptors [10] . However, in addition to the postjunctional blocking action of Org 9426, which results in an overall reduction in the amplitudes of the EPC, we have provided some evidence pointing to a prejunctional action of Org 9426. Thus Org 9426 increased the variance of the amplitudes of EPC in the plateau portion of the train, and hence reduced EPC quantal content as assessed by the variance method. The variance method overestimates quantal content with "normal", transmitter release [19] , as in the present investigations, but it does allow a reasonably accurate comparative measure of release in the absence and presence of a drug. Thus Org 9426 produced an approximate 70 % reduction in quantal content and mobilization rate during the plateau portion of the train. Such observations with' other agents have been used as supportive evidence for the involvement of the putative prejunctional nicotinic autoreceptor in the control of transmitter mobilization [5] [6] [7] . In terms of the relative pre-and postjunctional blocking activities of Org 9426 in comparison with those of other neuromuscular blocking drugs, particularly its parent compound vecuronium, it is only possible to make comparisons with previous data for vecuronium recorded under conditions similar to those utilized here. Thus, in the study of Gibb and Marshall [11] , vecuronium 1.5 x 10"* mol litre" 1 produced an approximate 90% reduction of the amplitude of the first EPC in the train (a measure of its postjunctional activity) and an approximate 65% rundown of EPC amplitudes in the plateau portion of the train (a measure of its prejunctional activity). Org 9426 at a concentration of 8 x 10"' mol litre" 1 produced a 68.2 (6.9)% (n = 7, -70 mV) reduction in the amplitude of the first EPC and a 68.1 (4.1) % (w = 7, -70 mV) rundown of EPC amplitudes in the plateau. Thus the relative pre-and postjunctional effects of Org 9426 were broadly similar to those of vecuronium, although there was a tendency of Org 9426 to produce more fade than vecuronium relative to their effects on single twitches.
We conclude, therefore, that the relative pre-and postjunctional actions of Org 9426 and vecuronium are similar and that any clinical differences in the action of the two compounds is unlikely to arise because of a preferential prejunctional action of either of the compounds. Hence, our results do not support the hypotheses of Wierda and colleagues [4] , that difference in the initial onset of neuromuscular block in vivo with Org 9426 and vecuronium could be because Org 9426, in addition to its established postjunctional action, exhibits a simultaneous, and more pronounced, inhibition of prejunctional nicotinic acetylcholine receptors than does vecuronium.
